Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Opsona Therapeutics logo — company profile

Opsona Therapeutics

Founded 2004 8 employees Series C Total: $65.20M Biotechnology, Health Care +1

General Information

Company Name Opsona Therapeutics
Founded Year 2004
Founders / Decision Makers
Team member
Employees 8
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Opsona Therapeutics. To contact Opsona Therapeutics, visit opsona.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Opsona Therapeutics compare?

A PDF of Opsona Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Opsona Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Opsona Therapeutics

Opsona Therapeutics, founded in 2004, is a pioneering drug development company specializing in the human immune system. The company's primary focus lies in identifying innovative approaches to prevent and treat autoimmune/inflammatory conditions, cancers, and infectious diseases. Opsona's drug discovery & development is centered around the role of Toll-Like Receptors (TLRs) and Inflammasome signaling in human immunology. Notably, since 2004, Opsona has established a unique and advanced pipeline of drugs, with research locations in Dublin (Ireland) and Lausanne (Switzerland). In October 2013, Opsona Therapeutics secured a significant investment of €3.00M in a Series C funding round. The round witnessed participation from a consortium of prominent investors including Amgen Ventures, Novartis Venture Fund, Omnes Capital, Sunstone Capital, Enterprise Ireland, BB Biotech Ventures, EMBL Ventures, Fountain Healthcare Partners, Roche Venture Fund, and Baxter International. This impressive list of investors speaks to the confidence and support the company has garnered within the biotechnology and healthcare industries. Opsona's innovative approach and the backing of established investors position the company as a compelling player in the biopharmaceutical landscape.

Business keywords: Drug development, Immunology, Autoimmune diseases, Inflammatory conditions, Cancer treatment, Infectious diseases, Toll-Like Receptors (TLRs), Inflammasome signaling, Innate immunity pathways, Research and development, Therapeutics, Ireland, Switzerland, Innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C €3.00M 10
Amgen Ventures Novartis Venture Fund Omnes Capital
Amgen Ventures, Novartis Venture Fund +8
02 Oct 2013
Series C €33.00M -
29 Apr 2013
Series B $4.60M -
16 Jun 2009
Series B €18.00M -
19 Feb 2009
Series A $6.60M -
24 Feb 2005

Opsona Therapeutics Alternatives & Competitors

View All Alternatives
Opsona Therapeutics vs
Nimbus Therapeutics
Nimbus Therapeutics United States

We develop breakthrough medicines for patients through precision small molecule design.

103 employees
Biotechnology, Health Care
Opsona Therapeutics vs
Asylia Therapeutics
Asylia Therapeutics

Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious diseases.

Series A
1 employees
Biotechnology, Health Care
Opsona Therapeutics vs
Olatec Therapeutics
Olatec Therapeutics United States

Leading the Development of Specific NLRP3 Antagonists,​ Mediator of Innate Inflammatory Response

Grant
15 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Opsona Therapeutics

Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like...
Opsona Therapeutics was founded in 2004.
Opsona Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Drug development, Immunology, Autoimmune diseases and Inflammatory conditions.
Opsona Therapeutics has approximately 8 employees.
Opsona Therapeutics has completed 5 funding rounds, raising a total of $65.20M. The latest funding stage is Series C.
Top alternatives and competitors to Opsona Therapeutics include Nimbus Therapeutics, Asylia Therapeutics, Olatec Therapeutics, Alder Biopharmaceuticals, Ventus Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Opsona Therapeutics and Nimbus Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Opsona Therapeutics, https://bouncewatch.com/company/opsona-therapeutics, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout